Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Octapharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

South Africa

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Patient Recruitment Starts for the International PRO-SID study Evaluating Panzyga® for Primary Prophylaxis

Contact the Supplier

Lead Product(s): Immune globulin, human - ifas

Therapeutic Area: Oncology Product Name: Panzyga

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 17, 2020

Details:

The double-blind, randomised, placebo-controlled, prospective, multicentre phase III PRO-SID study was designed to assess the efficacy and safety of Panzyga®, a human immunoglobulin for intravenous administration, as primary prophylaxis in patients with CLL and SID.